Daiwa Securities Group
MRNS

Daiwa Securities Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Daiwa Securities Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-202
Closed – – 1351
2024
Q3 		$0 Hold
202
– – ﹤0.01% 1357
2024
Q2 		$0 Hold
202
– – ﹤0.01% 1382
2024
Q1 		$2K Buy
202
+144
+248% +$1.4K ﹤0.01% 1285
2023
Q4 		$1K Hold
58
– – ﹤0.01% 1315
2023
Q3 		$0 Hold
58
– – ﹤0.01% 1349
2023
Q2 		$1K Hold
58
– – ﹤0.01% 1312
2023
Q1 		$0 Hold
58
– – ﹤0.01% 1330
2022
Q4 		$0 Hold
58
– – ﹤0.01% 1409
2022
Q3 		$0 Hold
58
– – ﹤0.01% 1416
2022
Q2 		$0 Hold
58
– – ﹤0.01% 1449
2022
Q1 		$1K Hold
58
– – ﹤0.01% 1357
2021
Q4 		$1K Hold
58
– – ﹤0.01% 1370
2021
Q3 		$1K Hold
58
– – ﹤0.01% 1293
2021
Q2 		$1K Hold
58
– – ﹤0.01% 1230
2021
Q1 		$1K Hold
58
– – ﹤0.01% 1241
2020
Q4 		$1K Buy
+58
New +$809 ﹤0.01% 1223
2018
Q4 		– Sell
-56
Closed -$2K – 1198
2018
Q3 		$2K Hold
56
– – ﹤0.01% 1132
2018
Q2 		$2K Hold
56
– – ﹤0.01% 1149
2018
Q1 		$1K Buy
+56
New +$1.33K ﹤0.01% 1157

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Daiwa Securities Group's MRNS Position: Q4 2024 in Review

Daiwa Securities Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 202 shares.

Daiwa Securities Group first reported a position in MRNS in Q1 2018 and held it in 19 quarters. The position peaked at $2K in Q1 2024. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Daiwa Securities Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Daiwa Securities Group sold 202 Marinus Pharmaceuticals, Inc shares in Q4 2024.
  • Daiwa Securities Group first reported a position in Marinus Pharmaceuticals, Inc in Q1 2018 and held it in 19 quarters.
  • Daiwa Securities Group's Marinus Pharmaceuticals, Inc position peaked at $2K in Q1 2024.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Daiwa Securities Group's 13F filing for Q4 2024, filed 7 Feb 2025.